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The phenotype of tumour-infiltrating lymphocytes (TILs) in solid
tumours, including breast tumours, has been well documented
using monoclonal and polyclonal antibodies on frozen and paraffin
tissue sections (Feradini et al, 1993; Head et al, 1993). Dendritic
cells (DCs) are potent antigen-presenting cells (APCs), whose role
is to capture and process antigen via the MHC II pathway for
presentation to CD4+ T cells. This results in T cell-mediated
immune responses against cells carrying specifically recognizable
antigenic targets (Williams et al, 1994). The presence of DCs in
human tumours has been associated with a better prognosis,
reduced tumour recurrence and fewer metastases (Huang et al,
1990; Becker, 1992; Tsujitani et al, 1992; Inoue et al, 1993). DCs
have therefore been proposed as playing a central role in the gener-
ation of an effective anti-tumour immune response (Becker, 1992).
The CD1a molecule is classed as a ‘non-conventional’ antigen-
presenting molecule with significant homology to ‘conventional’
MHC class I and MHC class II molecules (Hanau et al, 1994) and
is integral in peptide acquisition and antigen presentation (Porcelli
et al, 1989). Many tumours of different histologies contain popula-
tions of CD1a-positive putative DCs within the lymphoid cell
infiltrate (Becker, 1992). Studies of gastric carcinoma (Huang et
al, 1990; Tsujitani et al, 1992) and transitional cell carcinoma
(Inoue et al, 1993) have shown an inverse correlation between
tumour grade and DC infiltrate. However, the distribution and
density of DCs within infiltrating ductal carcinoma (IDC) and
ductal carcinoma in situ (DCIS) of the breast has not been previ-
ously described.
Within the normal lympho reticular system, only Langerhans
cells (LCs), some skin DCs (Yu et al, 1989; Osterhoff et al, 1994;
Williams et al, 1994) and some thymic cells (Williams et al, 1994)
express CD1a. No other normal lymphoid cells have been shown
to express CD1a. High CD1a and MHC molecule expression on
LCs/DCs may explain their potency as APCs. The expression of
CD1a appears to be dependent on the functional state of the DCs,
as CD1a expression is high when cells are capturing antigen and is
down-regulated when antigen presentation is occurring (Moulon et
al, 1991). Freshly isolated bone marrow and blood DCs are CD1a
negative, as are most APCs resident in lymphoid organs (Williams
et al, 1994). In addition to CD1a, the polyclonal antibody S100 has
been used by several groups as a DC identification marker
(Nakano et al, 1989; Huang et al, 1990; Tsujitani et al, 1992; Inoue
et al, 1993). This antibody reacts with the cytoplasmic protein 
S-100b, which is present in neurones, melanocytes and some DCs
(Krenacs et al, 1993).
It is unclear why the anti-tumour immune response is ineffec-
tive; however, possible mechanisms include low DC numbers,
poor antigen capture or presentation, failure of DC maturation,
lack of IL-2 cytokine production, down-regulation of cytokine
receptors (Coventry et al, 1996) and failure of expression of co-
stimulatory molecules such as B7-1 or B7-2 (June et al, 1994) or
CTLA4 ligand (Johnson and Jenkins, 1992). The number of DCs
in human breast carcinomas has not been sufficiently documented,
therefore this study aimed to identify putative DCs in breast
tumours. Anti-CD1a monoclonal antibody (MAb) was used on
fresh-frozen tissue sections to (1) investigate DC density, (2)
examine the spatial relationship of DCs to tumour and immuno-
logical cells and (3) correlate the DC infiltrate with different histo-
logical tumour grades (Scarfe/Bloom and Richardson grading
system).
METHODS
Tissues and processing
Frozen tissue was obtained from 52 ductal breast carcinomas (by
tumour grade: DCIS, 7; IDC I, 11; IDC II, 19; IDC III, 15), with
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nine non-tumour control samples obtained from breast tissue
distant from the tumour site. Control samples were histologically
free of tumour cells. Tissue was embedded in OCT (Tissue Tek,
Miles Laboratories) and snap frozen in liquid nitrogen. Serial
sections (4 mm) were cut (Ames Cryostat, Tissue Tek) onto gela-
tinized slides, acetone fixed (10 min) and air dried.
Immunohistochemical techniques
Antibodies were mouse anti-human monoclonals with the excep-
tion of S-100 (rabbit anti-human polyclonal) diluted in 10%
normal horse serum (NHS, Sigma) at varying concentrations:
CD1a at 1:1000 (Dako, Denmark), S100 at 1:80 000 (Dako,
Denmark), Cam 5.2 at 1:500 (Becton Dickinson), isotype controls
IgG1, IgG2a (supernatants at 1/10, L. Ashman, IMVS Adelaide),
second antibody biotinylated rabbit anti-mouse IgG/IgM at 1/500
(Dako) and streptavidin–HRP at 1:1000 (Pierce, USA).
Single immunostaining protocol
All reactions were carried out at room temperature with phos-
phate-buffered saline (PBS) washes in triplicate between incuba-
tions. Sections were blocked with 10% NHS (30 min), incubated
overnight in a humidified chamber with the primary antibody,
followed by biotinylated second antibody incubation (1 h).
Endogenous peroxidase blockade (0.5% hydrogen peroxide;
methanol, 20 min) was followed by streptavidin–HRP incubation
(1 h). High-sensitivity nickel chloride-enhanced diaminobenzi-
dene (nickel DAB) techniques were used (Coventry et al, 1994,
1995), and sections were counterstained with methyl green.
Double staining protocol
The primary antibody concentrations were increased, and incuba-
tion times were shortened to 1 h. The first primary antibody was
visualized using nickel DAB, and the second primary antibody
was visualized using DAB/imidazole.
Identification of putative DCs
There was no single specific MAb that identified DCs. Two of the
most commonly used MAbs, anti-CD1a and anti-S100, were
tested and compared to assess the MAb that produced the most
reliable and consistent staining results in breast tumour tissue. The
sections were visually assessed for (1) the presence or absence
of specific cell staining that demonstrated distinctive DC
morphology and (2) comparison of the location of positive cells by
relationship to tissue landmarks in serial sections using different
MAbs.
Identification of tumour cells
Epithelial cells within the tumour were stained with Cam 5.2, a
MAb that reacts with secretory epithelia of normal tissue as well
as epithelial adenocarcinomas (Makin et al, 1984).
Characterization of cellular infiltrate
Infiltration of CD1a+ cells was characterized using: (1) visual
quantitation, (2) cell distribution within the tumour, (3) correlation
with other infiltrating cell types and (4) clustering patterns with
associated infiltrating and/or tumour cells.
Visual quantitation
Density was assessed by calculating the mean of 50 random fields
per frozen section (field size 0.375 mm diameter, 0.11 mm2, 400 ´
magnification) (Dunnill, 1968), enabling a representative estima-
tion of the density and distribution of different cell types in the
infiltrate to be compared with CD1a+ cells.
Distribution assessment
Location of positive cells in relation to tissue landmarks such as
ducts, stroma or tumour cell nests enabled comparisons of
different distribution patterns to be made between different histo-
logical grades, as well as between cells positive for different
MAbs.
Statistics
Non-parametric statistics were used for all calculations. For tests
of statistical significance between groups, the Kruskal–Wallis
analysis of variance and Mann–Whitney U-tests were used.
Correlations were analysed with the Spearman rank linear correla-
tion test.
RESULTS
S-100 was observed to react with both putative DCs and epithelial
elements in breast tissues, which therefore made specific interpre-
tation difficult, while CD1a specifically stained a population of
cells with a predominantly typical dendritic morphology, as well
as occasional cells that did not appear to have dendrites (Figure 1).
As a result of these findings, CD1a was used in all staining exper-
iments to identify putative DCs.
Density and distribution of CD1a+ cells
Density
CD1a+ cells were present in 84% of tumour samples (n = 52), and
in 22% of non-tumour samples (n = 9). The density of the infiltrate
was highly variable between individual tumours (range 0–46 per
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Figure 1 High-power photomicrograph of CD1a+ cells in 5 mm frozen
sections of human breast tumour. The cells show a predominantly dendritic
morphology. Most assume irregular shapes, although some appear to be
rounded. This may represent their orientation in the plane of the tissue
section (600 ´ magnification)942 EE Hillenbrand et al
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high-power field), but there was no correlation with tumour grade
(Mann–Whitney, P > 0.05). CD1a+ cell density was significantly
higher in tumour than in non-tumour tissue (Kruskal–Wallis, P =
0.0192, n = 61). Figure 2 shows the density of CD1a+ cell infiltrate
by tumour grade. There was no correlation between CD1a+ cell
density and tumour grade.
Distribution
Visual assessment identified periductal distribution of CD1a+ cells
in low-grade tumours, with CD1a+ cells intermixed with tumour
cells in higher grade tumours. In both low- and high-grade
tumours, CD1a+ cells appeared to make contact with tumour cells.
The CD1a+ tumour cell association was demonstrated with a
double staining technique using anti-CD1a and anti-CAM5.2, with
the result that in 90% of tumours the CD1a+ cells were clustering
with CAM 5.2+ cells. Figure 3 shows this CD1a/CAM5.2 cell
association. CD1a+ cells were predominantly located either
periductally or within the ducts, whereas CD3+ cells were predom-
inantly located in the tumour stroma (Figure 4).
DISCUSSION
In the normal breast tissue microenvironment, CD1a+ putative
DCs are present in very low numbers, if at all. This study has iden-
tified CD1a+ cells with predominantly dendritic morphology
within the immune cell infiltrate of 84% of the breast tumours
examined. It is highly likely that these cells are DCs, with the
expression of CD1a molecules indicating that these cells are
actively involved in antigen recognition and capture. The identifi-
cation in this study of significantly higher densities of CD1a+ cells
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Figure 2 The density of CD1a+ cells in ductal carcinoma of the breast.
There was no significant difference in density between tumour grades but, in
the non-tumour tissue, the infiltrate was significantly lower or absent
(P < 0.05). Eighty-four per cent of the tumour samples had an infiltrate of
CD1a+ cells compared with 22% of non-tumour samples. The results are
expressed as mean cell counts per high-power field (HPF), with 50 HPFs
counted per sample at 400 ´ magnification. Bar represents median values
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Figure 3 (A) A 5 mm frozen section of a low-grade human ductal breast
carcinoma. Tumour cells are identified using Cam 5.2 and
diaminobenzedine/imidazole (50 ´ magnification). (B) Serial section showing
darker staining CD1a+ cells, visualized using diaminobenzedine/nickel
chloride (50 ´ magnification). (C) Double-stained section, showing both
CD1a+ (darker cells) and Cam 5.2+ (lighter cells) in close association with
each other (50 ´ magnification)CD1a positive cells in breast tumours 943
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in breast tumour tissue than in normal breast tissue indicates that
in breast cancer, as in other tumours studied, CD1a+ cells are
attracted to the tumour environment where they have the potential
to participate in the immune response against the tumour. It is
unclear whether DC entry is a primary or secondary event due to
cytokines produced by either monocyte/macrophages, lympho-
cytes and/or transformed cells. Both granulocyte–macrophage
colony-stimulating factor (GM-CSF) and IL-2 have been shown to
induce migration of DCs into tissues (Kradin et al, 1996). IL-2R is
expressed by DCs in rats and anti-IL-2R has been shown to block
IL-2-induced DC migration (Kradin et al, 1996). IL-10 release
from tumour cells may be important in inactivation of CD1a-
positive cells (Enk et al, 1997). However, IL-10 was expressed at
low levels in tumour and non-tumour tissue (unpublished).
The evidence regarding the origin of these cells is conflicting,
with some studies indicating that tissue (or intratumoral) DCs and
LCs may be derived from separate lineages (Steinman et al, 1997;
Strunk et al, 1997). Alternatively, there is some emerging evidence
from lymphoscintigraphic studies to suggest that lymph, and
presumably LCs, from breast skin may drain into the breast tissue
in transit to the axillary lymph nodes (Borgstein et al, 1997;
Giuliano et al, 1997). This theory gains some support from the
observation that LCs are CD1a positive and have been shown to
lose Birbeck granules (BGs) following 24 h culture (Richters et al,
1994), a finding that indicates that the tissue microenvironment
can influence the phenotype of LCs (or DCs). In addition, CD1a-
positive LCs lacking BGs have been identified in the skin
(Mommaas et al, 1994; Richters et al, 1994).
A close spatial association was demonstrated between CD1a+
cells and tumour cells using double staining with CD1a and CAM
5.2 antibodies, confirming observations by others in different
tumour types (Kato et al, 1990; Kondo et al, 1990; Chaux et al,
1993). Periductal distribution of CD1a+ cells was noted in DCIS
and grade I tumours, and in higher grade tumours CD1a+ cells
were intermixed with tumour cells. This study did not show a
correlation between CD1a+ cell density and tumour grade, whereas
some studies of other tumour types have found negative correla-
tions between tumour grade and DC infiltrate (Becker, 1992).
Tumours that have shown such a negative correlation are predom-
inantly tumours of surface epithelia, such as oesophageal (Becker,
1992), transitional cell (Inoue et al, 1993), cervical (Nakano et al,
1989) and gastric carcinoma (Huang et al, 1990; Tsujitani et al,
1992). These tissues are normally exposed to external antigens,
and therefore contain a population of DCs as part of their normal
cellular composition, which may partly explain the discrepancy in
experimental outcomes.
It is also worth noting that differences in experimental condi-
tions, which have not been consistent between studies, may have
contributed to differences between results. High-sensitivity nickel-
enhanced DAB detection methods used in this study are estimated
to be 7–10 times more sensitive than DAB alone (Coventry et al,
1994). In addition, some studies examining DC infiltrates in
tumours have used S100 (Nakano et al, 1989; Huang et al, 1990;
Tsujitani et al, 1992; Inoue et al, 1993), while others have used
CD1a (Rucci et al, 1991). However, it has been demonstrated that
not all S100-positive cells are DCs. Barrett et al (1994) demon-
strated, using a double-staining protocol, that 41–84% of the
S100-positive cells in the stratum basale of the oral mucosa were
also positive for melanin, indicating that these cells were probably
melanocytes that could potentially be mistaken for DCs. S100 may
have a cytoskeletal function, which perhaps explains its presence
in cells with little in common other than dendritic morphology.
Alternatively, a common embryological origin from neural crest
may exist.
The inclusion of DCs in immunotherapeutic protocols is
becoming feasible. Recent methods for isolation of tumour-
infiltrating DCs from human breast cancers may permit functional
studies of the DCs and their modulation of the anti-tumour immune
response (Coventry et al, 1997). Blood DC separation and culture
techniques have also advanced (Hart, 1997; Lotze et al, 1997;
Schuler and Romani, 1997), and immunotherapy using DCs primed
with tumour peptide antigens may offer a more specific molecular
approach than conventional cancer chemotherapeutic treatments
(Elsasser Beile and von Kliest, 1993). Adoptive immunotherapy
A
B
0 200m
Figure 4 (A) Frozen section of ductal carcinoma in situ, showing an
infiltration of a transformed duct by CD1a+ cells. The surrounding tumour free
stroma is devoid of CD1a+ cells (25 ´ magnification). (B) CD3+ cells and their
distribution near the same duct. It can be clearly seen that these cells are
located periductally and within the tumour-free stroma (25 ´ magnification)using autologous APCs may provide a strategy for enhanced
immune responses reproducing that seen in early tumour growth.
Alternatively, recruitment of endogenous naive DCs using GM-
CSF to promote capture of vaccinated tumour peptides (Dranoff et
al, 1997) could provide an effective anti-tumour strategy.
It may also be possible to use the density of infiltrating CD1a+
cells as a prognostic indicator by relating their density to survival
and recurrence rates in longitudinal follow-up studies 5 and 10
years following surgical resection. The activation status of DCs
within tumours is a further topic currently under investigation.
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